期刊文献+

典型两用性生物技术的潜在生物安全风险分析 被引量:9

Potential biosafety risks of typical dual-use biotechnology
原文传递
导出
摘要 生物技术是典型的两用性技术。一方面,利用生物技术开展生命科学研究可对公共卫生、农作物、畜牧业和环境领域的发展起到积极推动作用;另一方面,当生物技术及利用生物技术开展的研究用于有害目的或被误用、谬用和滥用时,将对公众健康和安全、农作物和其他植物、动物、环境、材料或国家安全构成威胁。本文对典型的两用性生物技术及其相关生物安全风险进行了阐述,以期为全面认识生物技术两用性奠定理论基础,并为加强两用性生物技术研究的有效监管提供理论依据。 Biotechnology is a typical dual-use technology. On one hand, researches on life science based on biotechnology can positively promote the development of public health, crops, animal husbandry and the environment. On the other hand, if biotechnology and researches using biotechnology are applied for harmful purposes,or are misused and abused, a threat will be posed to public health and safety, crops and other plants, animals,environment, materials, or national security. This article illustrates typical dual-use biotechnology and related biosafety risks, aiming to lay a theoretical foundation for a comprehensive understanding of dual-use biotechnology,and to provide a theoretical basis for strengthening effective supervision on the researches based on dual-use biotechnology.
作者 张鑫 王莹 刘静 李萍萍 孙燕荣 ZHANG Xin;WANG Ying;LIU Jing;LI Ping-ping;SUN Yan-rong(China National Center for Biotechnology Development,Beijing 100039,China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2020年第13期1495-1500,共6页 Chinese Journal of New Drugs
基金 2019年国家社会科学基金重大项目(19ZDA109)。
关键词 生物技术 两用性 生物安全风险 biotechnology dual-use biosafety risks
  • 相关文献

参考文献8

二级参考文献69

  • 1马国,邓盛齐.纳米技术在药学中的研究应用进展[J].国外医药(抗生素分册),2004,25(5):233-237. 被引量:12
  • 2Bawa R, Johnson S. Emerging Issues in Nanomedicine and Ethics [M]// Allhoff F, Lin P. Nanotechnology &Society: Current and Emerging Ethical Issues. Kalamazoo San Luis Obispo USA : Western Michigan University California Polytechnic State University, 2008:207--223. 被引量:1
  • 3Jong W H de, Roszek B, Geertsma R E. Nanotechnology in medical applications: possible risks for human health[R/OL]. (2005-- 10-- 02)[2008-- 08-- 30]. http://nanobio-- raise, org. 被引量:1
  • 4冯卫东.石棉状的碳纳米管可引发罕见的恶性问皮瘤[EB/OL].(2008一06-02)[2008-06-09].http:/scitech.people.com.cn/G13/7326465.html. 被引量:1
  • 5Scientific committee on emerging and newly identified health risks. European Commission: health & consumer protection directorategeneral [EB/OL]. (2005 -- 09 -- 28) [2008 -- 08 -- 30]. http://nano- bio-- raise, org/group/editors/menus/main/aetivities/view. 被引量:1
  • 6Allhoff F. On the autonomy and Justification ot Nanoethics[J]. Nanoethics, 2007(1) :185--210. 被引量:1
  • 7Sheetz T, Vidal J, Pearson T D, et al. Nanotechnology: Awareness and societal concerns[J/OL]. (2005 -- 06 -- 09 ) [2008 -- 04 -- 21]. http ://www. sciencedirect, com/science? _ob. 被引量:1
  • 8Wagner V, Dullaart A, Bock A K,et al. The emerging nanomedicine landscape[J]. Nature Biotechnology, 2006,24 (10):1211 -- 1217. 被引量:1
  • 9Commissioner of Food and Drugs. Nanotechnology: A Report of the U. S. Food and Drug Administration of America[R/OL]. (2007-- 07 -- 25) [2008 -- 07 -- 27]. http ://www. fda. gov/nanotechnology/ taskforce/report2007, pdf. 被引量:1
  • 10Gaspar R. Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharrnaceuticals[J]. Nanomedicine, 2007,2 (2) : 143-- 147. 被引量:1

共引文献50

同被引文献143

引证文献9

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部